What is the market's earnings forecast for Viatris next quarter?

What were the key takeaways from Viatris’s earnings call?

What is the revenue and EPS growth rate for Viatris year over year?

What is Viatris's latest dividend and current dividend yield?

What is Viatris's gross profit margin?

What does Viatris do and what are its main business segments?

What factors drove the changes in Viatris's revenue and profit?

What guidance did Viatris's management provide for the next earnings period?

- **Operational Growth**: 1% Q3 revenue growth (ex-Indore), driven by generics and established brands.
- **Pipeline Momentum**: Fast-acting meloxicam NDA submission by year-end; selatogrel/cenerimod enrollment on track.
- **Capital Allocation**: $500M share buybacks YTD; $920M total capital returned in 2025.
- **Strategic Review**: Multiyear cost savings with reinvestment in growth, details in Q1 2026.
- **Japan Expansion**: Aculys acquisition adds CNS assets, strengthening innovative brands portfolio.

**【CEO Summary】**
- Delivered strong Q3 performance with 1% operational revenue growth (excluding Indore), driven by generics and established brands.
- Advanced strategic review to identify multiyear cost savings, with reinvestment in growth opportunities.
- Pipeline progress: fast-acting meloxicam NDA submission expected by year-end, selatogrel and cenerimod enrollment on track.
- Acquired Aculys Pharma in Japan, adding CNS assets and strengthening innovative brands portfolio.

**【CFO Financial Commentary】**
- Total revenue $3.76B, down 1% YoY due to Indore impact; adjusted EBITDA $1.1B, up 12% YoY.
- Free cash flow $658M, enabling $500M share buybacks YTD and $920M total capital return.
- 2025 guidance updated: 2-3% operational revenue growth, adjusted EBITDA $4.3-4.5B.

**【CCO Commercial Highlights】**
- Fast-acting meloxicam go-to-market strategy finalized, targeting acute pain with opioid-sparing potential.
- Low-dose estrogen patch expected to launch mid-2026, addressing unmet need for contraception.
- Japan expansion with Aculys acquisition, adding pitolisant and spydia for CNS indications.
- EpiPen share stable at 24-25%, driven by Europe and Canada relaunches.

**【Q&A Highlights】**
- Indore resolution: FDA reinspection pending; redundancies built with third-party vendors.
- Meloxicam: $500M peak sales potential, with Phase III data supporting opioid-sparing label.
- Strategic review: savings to be reinvested in pipeline and M&A, with details in Q1 2026 investor event.
- 2026 outlook: new product revenue expected to meet $450-550M target, excluding Indore.

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 3% operational growth ex Indore, driven by Europe and China.
- **Pipeline Breakthroughs**: 5/6 Phase III readouts positive; meloxicam targeting $80B market; ophthalmology assets advancing.
- **Financial Strength**: $630M+ capital returned YTD; gross margin stable at 56.6%.
- **Strategic Focus**: Balancing BD investments with shareholder returns; enterprise-wide review for '26+ growth.
- **Risk Management**: No material tariff impact expected in '25; 50% U.S. manufacturing mitigates supply chain risks.

**【CEO Summary Section】**
- **Strong Q2 Performance**: 3% divestiture-adjusted operational revenue growth, driven by Europe and Greater China. 5 of 6 Phase III readouts achieved positive results, including meloxicam for acute pain and ophthalmology assets.
- **Pipeline Momentum**: Fast-acting meloxicam targeting $80B U.S. acute pain market; selatogrel and cenerimod Phase III enrollment progressing; sotagliflozin approved in UAE.
- **Capital Allocation**: $630M returned to shareholders YTD (including $350M buybacks); balancing BD investments with shareholder returns.
- **Strategic Review**: Evaluating all aspects of business for '26+ growth; update expected in Q3.
- **Regulatory Progress**: FDA approval for darunavir at Nashik; Indore remediation nearing completion.

**【CFO Financial Commentary】**
- **Q2 Results**: Total revenue $3.58B (-2% YoY, +3% ex Indore impact). Adjusted gross margin 56.6%, in line with expectations.
- **Regional Performance**: Europe +2%, North America -11% (Indore impact), Emerging Markets +1%, China +9%.
- **Cash Flow**: $167M free cash flow; $241M ex transaction costs. On track for $630M+ capital return.
- **Guidance**: Reaffirming 2025 ranges; expect top-half of revenue and EPS guidance due to operational momentum and FX tailwinds.
- **Risk Management**: Monitoring U.S. tariff developments; no material impact expected in '25.

**【Q&A Key Highlights】**
- **Tariffs & Supply Chain**: 50% U.S. manufacturing; India accounts for 10% low-margin OSD. No material '25 impact anticipated.
- **China Growth**: 9% Q2 growth driven by e-commerce, retail, and private hospitals; expect low/mid-single digit growth in H2.
- **Meloxicam Launch**: $80B U.S. acute pain market; NDA filing by end-2025; commercial strategy under development.
- **Pipeline Phasing**: XULANE NDA submission in coming weeks; MR-141 FDA filing H2 '25; selatogrel/sotagliflozin readouts '26.
- **Strategic Review**: Focus on cost optimization and efficiency; cost savings expected but details TBD.


Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

- **Q1 2025 Performance**: $3.3B revenue (-2% YoY) with 3 key Phase 3 wins
- **Pipeline Momentum**: Fast-acting meloxicam Phase 3 success; XULANE LO NDA in H2
- **Capital Return**: $450M+ returned YTD; 2025 buyback target $500-650M
- **Tariff Mitigation**: 50%+ US revenue from domestic manufacturing; $8.5B doses/year in US
- **Indore Recovery**: 60%+ product recovery potential by 2026
- **Key Launches**: Iron Sucrose, Octreotide, glucagon expected H2 2025


**【CEO Opening Remarks】**
- Q1 2025 total revenue: $3.3 billion (down 2% YoY on operational basis due to Indore facility impact). 
- Key highlights: 
  - 3 positive Phase 3 readouts (fast-acting meloxicam, XULANE LO, EFFEXOR XR)
  - $450M capital returned to shareholders (30% via share buybacks)
  - On track for re-inspection of Indore facility mid-year
  - 2025 pipeline includes 6 Phase 3 readouts with 3 already completed

**【CFO Financial Breakdown】**
- GAAP net income: $2.9B (includes non-cash goodwill impairment charge)
- Adjusted EBITDA: $1.1B (down 6% YoY due to Indore impact)
- Free cash flow: $493M (Q1) / $1.7B annual target
- Capital allocation: 60%+ to share buybacks ($500-650M target)
- 2025 guidance reaffirmed despite $140M Indore Q1 impact

**【R&D Pipeline Updates】**
- Fast-acting meloxicam: 
  - Phase 3 studies met all endpoints vs. placebo and opioid comparator
  - Targeting FDA submission by end-2025
  - Potential $500M+ peak sales
- XULANE LO patch: 
  - Phase 3 results show 98% efficacy with mild side effects
  - NDA submission planned for H2 2025
- Selatogrel/Cenerimod: 
  - Selatogrel Phase 3 readout expected 2026
  - Cenerimod expanded to 100+ countries post-rights deal

**【Q&A Highlights】**
- Tariff mitigation: 
  - 50%+ US revenue from domestic manufacturing
  - $8.5B doses produced annually in US
  - Exploring new US manufacturing capacity
- Meloxicam launch strategy: 
  - Targeting 70M+ acute pain patients
  - Inpatient and outpatient dual channel strategy
  - Fast-acting profile demonstrated (median 95min relief vs. 338min placebo)
- Indore recovery: 
  - 40% of impact from lenalidomide (permanent loss)
  - 60%+ recovery potential for other products in 2026


Viatris (VTRS)-8 May 25-2025 Q1 Earnings call transcript

- **2024 Strong Financials**: 2% revenue growth, $4.7B EBITDA, $2.6B free cash flow, and $3.7B debt reduction.
- **2025 Challenges**: $500M revenue hit from Indore, 1% operational decline, and $385M EBITDA impact.
- **Pipeline Momentum**: 6 Phase III readouts, sotagliflozin cardiovascular benefits, and cenerimod/selatogrel enrollment acceleration.
- **Capital Return**: $500-650M buybacks, 70% of $1B capital returned to shareholders.
- **China Growth**: Dymista and Breyna launches, leveraging e-commerce for chronic disease brands.

**【CEO 2024 Performance Overview】**
- Total revenue growth of 2% on a divestiture-adjusted operational basis, with adjusted EBITDA of $4.7 billion and free cash flow of $2.6 billion.
- New product revenue reached $582 million, driven by complex generics and innovative assets like selatogrel and cenerimod.
- Debt reduction of $3.7 billion achieved, with gross leverage target of 2.9x.
- Indore facility issues expected to impact 2025 revenue by $500 million and EBITDA by $385 million due to supply disruptions and penalties.

**【CFO 2025 Financial Guidance】**
- Total revenue decline of 1% on an operational basis, with FX headwinds of 2-3%.
- Adjusted EBITDA margin expected to decline due to Indore impact, base business price erosion, and increased supply costs.
- Share buybacks of $500-650 million planned, with total capital return of $1 billion.
- Free cash flow projected at $2 billion, supporting debt reduction and shareholder returns.

**【R&D Pipeline Updates】**
- 10 Phase III molecules in development, with 6 readouts expected in 2025 (e.g., meloxicam for acute pain, MR-139 for blepharitis).
- Cenerimod and selatogrel trials progressing, with enrollment acceleration for cardiovascular studies.
- Sotagliflozin demonstrated cardiovascular benefits, with regulatory submissions starting in 2025.

**【Commercial Strategy】**
- Europe expected to grow due to new product launches and strong generics performance.
- North America faces headwinds from Indore and competition, but complex injectables like iron sucrose and glucagon are key growth drivers.
- Emerging markets to benefit from ARV expansion and cardiovascular portfolio growth in Latin America.
- China to leverage e-commerce and private hospitals for brand growth, despite policy risks.

**【Indore Remediation】**
- Remediation 50% complete, with reinspection requested in late 2025.
- 11 U.S.-listed products impacted, including lenalidomide, with no additional exceptions granted.
- Short-term supply disruptions in Europe and emerging markets, with potential long-term volume recovery.

**【Q&A Key Takeaways】**
- 2026 outlook: Base business growth resuming, with pipeline launches offsetting Indore impact.
- Capital allocation: 50% to shareholders, 50% to accretive M&A, with flexibility for share buybacks.
- R&D focus: Accelerating cenerimod and selatogrel timelines, with Phase III data expected late 2026.
- FDA interactions: Nashik facility inspection pending, with no other compliance issues across 26 manufacturing sites.

VTRS

VTRS fundamentals

Earnings Call

You can ask Aime